企業プロフィール
Xeris Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- XERS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
8.52 USD (-0.93%)
終値
最終更新: 2026年8月17日
1.04B USD
時価総額
株価変動の要因
As of Aug 17, 2026, XERS closed down 0.93% at $8.52. No new same-company headline was identified in the current news window.
企業概要
Specialty Biopharmaceutical Portfolio
Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability.
Endocrine Products
Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome. Gvoke is a ready-to-use liquid glucagon for severe hypoglycemia. Keveyis is an oral therapy for primary periodic paralysis. Together, the portfolio gives Xeris a multi-product commercial platform serving specialist prescribers and patients with chronic or episodic endocrine disorders.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。